



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYDARCBDF (IV Cycle 2+) (Page 1 of 3)

DOCTOR'S ORDERS Ht \_\_\_\_\_ cm Wt \_\_\_\_\_ kg BSA \_\_\_\_\_ m^2
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form
DATE: \_\_\_\_\_ To be given: \_\_\_\_\_ Cycle #: \_\_\_\_\_
Date of Previous Cycle: \_\_\_\_\_
\*\*\*\*Ensure Red Blood Cell Phenotype and Group and Screen for all patients prior to Cycle 1\*\*\*\*
[ ] Delay treatment \_\_\_\_\_ week(s)
[ ] CBC & Diff, Platelets day of treatment
• Proceed with bortezomib dose day 1 as written, if within 96 hours ANC greater than or equal to 0.5 x 10^9/L, platelets greater than or equal to 30 x 10^9/L, bilirubin less than or equal to 1.5 x upper limit of normal
• If CBC prior to day 1 show ANC less than 1.5 x 10^9/L or platelets less than 100 x 10^9/L then:
• May proceed with bortezomib Days 8, 15, 22 as written, if within 48 hours ANC greater than or equal to 0.5 x 10^9/L, platelets greater than or equal to 30 x 10^9/L
• Proceed with cyclophosphamide dose as written, for entire cycle, if day 1 lab is within 96 hours ANC greater than or equal to 1.0 x 10^9/L, platelets greater than or equal to 80 x 10^9/L and CrCl greater than or equal to 10 mL/min
• Proceed with daratumumab day 1 dose as written, if within 96 hours (or within 48 hours for day 15) ANC greater than or equal to 1.0 x 10^9/L, platelets greater than or equal to 50 x 10^9/L
Dose modification for: [ ] Hematology: \_\_\_\_\_ [ ] Other Toxicity: \_\_\_\_\_
Proceed with treatment based on blood work from \_\_\_\_\_
CHEMOTHERAPY:
CYCLOPHOSPHAMIDE - Cycles 2 to 9
cyclophosphamide 300 mg/m^2/day x BSA x ( \_\_\_\_\_ %) = \_\_\_\_\_ mg PO weekly on days 1, 8, 15 and 22 (round to nearest 25 mg)
BORTEZOMIB - Cycles 2 to 9
• If patient is VZV seropositive and/or at physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg daily while on bortezomib and/or daratumumab and for four weeks after discontinuation
bortezomib [ ] 1.5 mg/m^2 or [ ] 1.3 mg/m^2 or [ ] 1 mg/m^2 or [ ] 0.7 mg/m^2 x BSA = \_\_\_\_\_ mg
subcutaneous injection weekly on days 1, 8, 15 and 22
STEROID: RN to use patient's therapeutic steroid (if applicable) as pre-med for daratumumab - refer to protocol
Cycles 2 to 9
[ ] dexamethasone [ ] 40 mg or [ ] 20 mg PO once weekly on days 1, 8, 15, and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, OR
[ ] dexamethasone \_\_\_\_\_ mg PO once weekly on days 1, 8, 15, and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, OR
[ ] predniSONE \_\_\_\_\_ mg PO once weekly on days 1, 8, 15, and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning
[ ] No steroid
DOCTOR'S SIGNATURE: SIGNATURE: UC:

**PROTOCOL CODE: MYDARCBDF (IV Cycle 2+)**  
(Page 2 of 3)

DATE:

**\*\*Have Hypersensitivity Reaction Tray and Protocol Available\*\***

**DARATUMUMAB**

If patient is VZV seropositive and/or at physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg daily while on bortezomib and/or daratumumab and for 4 weeks after discontinuation

**DARATUMUMAB PREMEDICATIONS:** Patient to take own supply. RN/Pharmacist to confirm.

**dexamethasone** as ordered in steroid section

**montelukast 10 mg** PO prior to each daratumumab

**acetaminophen 650 mg** PO prior to each daratumumab. Repeat **acetaminophen 650 mg PO** every 4 hours when needed

Select one of the following:

**loratadine 10 mg** PO prior to each daratumumab, then **diphenhydrAMINE 50 mg** IV every 4 hours when needed

OR

**diphenhydrAMINE 50 mg**  PO or  IV prior to each daratumumab. Repeat **diphenhydramine 50 mg** IV every 4 hours when needed

**DARATUMUMAB**

**CYCLE 2, Days 1, 8, 15, and 22:**

**daratumumab 16 mg/kg** x \_\_\_\_\_ kg = \_\_\_\_\_ mg IV in 500 mL NS (use 0.2 micron in-line filter)

**CYCLES 3 to 6, Days 1 and 15:**

**daratumumab 16 mg/kg** x \_\_\_\_\_ kg = \_\_\_\_\_ mg IV in 500 mL NS (use 0.2 micron in-line filter)

**CYCLES 7 to 9, Day 1:**

**daratumumab 16 mg/kg** x \_\_\_\_\_ kg = \_\_\_\_\_ mg IV in 500 mL NS (use 0.2 micron in-line filter)

**CYCLE 10 onwards, Day 1:**

**daratumumab 16 mg/kg** x \_\_\_\_\_ kg = \_\_\_\_\_ mg IV in 500 mL NS (use 0.2 micron in-line filter) x \_\_\_\_\_ cycle(s)  
(max 3 cycles)

**Infusion rate for cycle 2 onwards: Physician to determine rate of infusion**

*If no reaction in the previous infusion or reaction is Grade 2 or less:*

Start at 200 mL/h. If no infusion - related reactions after 30 minutes, infuse the remainder at 450 mL/h (Rapid infusion)

*OR If reaction in the previous infusion is Grade 3:*

Start at 100 mL/h. If no infusion-related reactions after 60 minutes, increase by 50 mL/h every 60 minutes to a maximum rate of 200 mL/h. Refer to protocol for modified starting rate if previous infusion reactions were experienced during infusion rate of greater than or equal to 100 mL/h (Slow infusion)

**Vitals monitoring:**

Vital signs immediately before the start, at the end of the infusion and as needed. Observe patient for 30 minutes after infusion. (Vitals and observation post-infusion not required after 3 treatments with no reaction).

**DOCTOR'S SIGNATURE:**

**SIGNATURE:**

**UC:**



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at [www.bccancer.bc.ca](http://www.bccancer.bc.ca) and according to acceptable standards of care

**PROTOCOL CODE: MYDARCBDF (IV Cycle 2+)**  
(Page 3 of 3)

<b>DATE:</b>	
<b>RETURN APPOINTMENT ORDERS</b>	
<p>For Cycles 3 to 9 book chemo on days 1, 8, 15, 22          For Cycles 10 and subsequent, book chemo on day 1</p> <p><input type="checkbox"/> Return in <b>four</b> weeks for Doctor and Cycle _____</p> <p><input type="checkbox"/> Return in <b>eight</b> weeks for Doctor and Cycles _____ and _____. Book chemo x 2 cycles.</p> <p><input type="checkbox"/> Return in <b>twelve</b> weeks for Doctor and Cycles _____, _____ and _____. Book chemo x 3 cycles</p> <p><input type="checkbox"/> Last Cycle. Return in _____ week(s).</p>	
<p><b>Laboratory:</b> Blood work done prior to next cycle must be done less than or equal to 4 days prior to the start date</p> <p><b>Day 1:</b> CBC &amp; Diff, platelets, sodium, potassium, creatinine, calcium, ALT, bilirubin, serum protein electrophoresis, serum free light chain levels</p> <p>CBC &amp; Diff, platelets on Day 8, 15, and 22 for current cycle if ANC on Day 1 is less than 1.5 or Platelets are less than 100:</p> <p><input type="checkbox"/> <b>CBC &amp; Diff, platelets</b> prior to Day 8, 15, and 22 treatment</p> <p><b>Cycles 2 to 6: Day 15:</b> CBC &amp; Diff, platelets</p> <p>If clinically indicated:</p> <p><input type="checkbox"/> immunoglobulin panel</p> <p><input type="checkbox"/> urine protein electrophoresis</p> <p><input type="checkbox"/> sodium, potassium</p> <p><input type="checkbox"/> ALT</p> <p><input type="checkbox"/> bilirubin</p> <p><input type="checkbox"/> creatinine</p> <p><input type="checkbox"/> See general orders sheet for additional requests</p> <p><input type="checkbox"/> Other tests:</p> <p><input type="checkbox"/> Consults</p>	
<b>DOCTOR'S SIGNATURE:</b>	<b>SIGNATURE:</b>
	<b>UC:</b>